1. Time to Clinically Relevant Fracture Risk Scores in Postmenopausal Women 
Margaret L. Gourlay, MD, MPH, Robert A. Overman, MPH, Jason P. Fine, ScD, Carolyn J. Crandall, MD, MS, John Robbins, MD, MHS, John T. Schousboe, MD, PhD, Kristine E. Ensrud, MD, MPH, Erin S. LeBlanc, MD, MPH, Margery L. Gass, MD, Karen C. Johnson, MD, MPH, Catherine R. Womack, MD, Andrea Z. LaCroix, PhD 
The American Journal of Medicine 
Volume 130, Issue 7, Pages 862.e e23 (July 2017)
DOI: /j.amjmed
Copyright © 2017 Elsevier Inc. Terms and Conditions

2. Figure
Study population for primary analyses of time to treatment-level or screening-level FRAX risk score. Of the 111,556 women who did not have a dual-energy x-ray absorptiometry bone density test, 57,276 were excluded, including those who had a past hip or clinical vertebral fracture or antifracture treatment (bisphosphonate or calcitonin) at their first study examination, or who did not have adequate data for a FRAX score calculation at 2 or more examinations, or one FRAX score and subsequent development of a competing risk. In the cohort of 54,280 women with adequate data for a FRAX-without- BMD score prior to censoring, 2 transitions were studied: transition to treatment-level FRAX score (10-year estimated risk of major osteoporotic fracture ≥20% or of hip fracture ≥3%), and transition to screening-level FRAX score (10-year estimated risk of major osteoporotic fracture ≥9.3%). By a similar exclusion process, 6096 eligible participants who had at least one bone mineral density test were identified and were studied for transition to treatment-level FRAX-with-BMD score. The 39,568 women excluded for screening-level or treatment-level FRAX scores at baseline could not participate in the main analysis, but their incidence of hip and clinical vertebral fracture was examined. BMD = bone mineral density; FRAX = Fracture Risk Assessment Tool.
The American Journal of Medicine  , 862.e e23DOI: ( /j.amjmed )
Copyright © 2017 Elsevier Inc. Terms and Conditions